Company & Sponsor Intelligence
Rhodes Pharmaceuticals, L.P.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting0
Completed1
Countries1
Therapeutic footprint
adhd
Indexed studies
NCT02677519A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT01239030Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →